Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

@article{citeulike:2084578, abstract = {SUMMARY: Aim: To investigate the effect of a thiazolidinedione on proteinuria in patients with non-diabetic renal disease. Methods: In an open-label randomized cross-over study, 40 adults with chronic non-diabetic renal disease completed the study. In a random fashion, one group was treated for 4 months with 4 mg of rosiglitazone first followed by a 4-month period of standard treatment. The opposite order was used for the second group. Results: Baseline urinary protein excretion rate was 1.45 g/24 h. On rosiglitazone, there was a drop of urinary protein level of 0.24 g/24 h (P = 0.045). In contrast, there was a trend for proteinuria to increase during the control period (0.12 g/24 h, P = 0.18). The urine protein level on rosiglitazone was lower than on usual treatment (0.36 g/24 h, P = 0.002, 95\% CI 0.15-0.58). There was a similar beneficial effect on systolic blood pressure which was reduced by rosiglitazone by 7.8 mmHg (P = 0.006, 95\% CI 2.6-13.1). Although average fasting glucose was only 5.8 mmol/L, there was a significant Spearman correlation between fasting glucose and a reduction in urinary protein levels (r = 0.34, P = 0.045). Conclusion: It is concluded that thiazolidinediones may have a role in the management of non-diabetic proteinuria of various aetiologies. In this study the average body mass index was 28.9 kg/m2. It will be important to repeat these studies in non-overweight subjects with non-diabetic proteinuria and in addition to trial maximal therapeutic doses of the thiazolidenedione.}, author = {Smith, Priscilla K. and Fairley, Kenneth F. and Farish, Stephen and Best, James D. and Proietto, Joseph }, citeulike-article-id = {2084578}, doi = {10.1111/j.1440-1797.2007.00903.x}, journal = {Nephrology}, number = {0}, pages = {???}, posted-at = {2007-12-10 04:14:19}, priority = {2}, title = {Reduction of proteinuria by rosiglitazone in non-diabetic renal disease}, url = {http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1797.2007.00903.x}, volume = {0}, year = {0} }

TY - JOUR ID - citeulike:2084578 L3 - citeulike-article-id:2084578 TI - Reduction of proteinuria by rosiglitazone in non-diabetic renal disease JF - Nephrology VL - 0 IS - 0 SP - ??? EP - ??? N2 - SUMMARY: Aim: To investigate the effect of a thiazolidinedione on proteinuria in patients with non-diabetic renal disease. Methods: In an open-label randomized cross-over study, 40 adults with chronic non-diabetic renal disease completed the study. In a random fashion, one group was treated for 4 months with 4 mg of rosiglitazone first followed by a 4-month period of standard treatment. The opposite order was used for the second group. Results: Baseline urinary protein excretion rate was 1.45 g/24 h. On rosiglitazone, there was a drop of urinary protein level of 0.24 g/24 h (P = 0.045). In contrast, there was a trend for proteinuria to increase during the control period (0.12 g/24 h, P = 0.18). The urine protein level on rosiglitazone was lower than on usual treatment (0.36 g/24 h, P = 0.002, 95% CI 0.15-0.58). There was a similar beneficial effect on systolic blood pressure which was reduced by rosiglitazone by 7.8 mmHg (P = 0.006, 95% CI 2.6-13.1). Although average fasting glucose was only 5.8 mmol/L, there was a significant Spearman correlation between fasting glucose and a reduction in urinary protein levels (r = 0.34, P = 0.045). Conclusion: It is concluded that thiazolidinediones may have a role in the management of non-diabetic proteinuria of various aetiologies. In this study the average body mass index was 28.9 kg/m2. It will be important to repeat these studies in non-overweight subjects with non-diabetic proteinuria and in addition to trial maximal therapeutic doses of the thiazolidenedione. AU - Smith, Priscilla AU - Fairley, Kenneth AU - Farish, Stephen AU - Best, James AU - Proietto, Joseph PY - 2000/// UR - http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1797.2007.00903.x ER -